TABLE 1.
Clinical and pathological outcome in MVA-SIV-vaccinated macaques following SIVsmE660 challenge
| Group and macaque | MHC-Ia | Survival (wks) | Pathology or clinical findingsc |
|---|---|---|---|
| Gag-Pol | |||
| H421 | B*29 | 212 | Pneumocystis pneumonia, LD |
| H423 | 70 | Bacterial bronchopneumonia, LD | |
| H457 | 107 | Amyloidosis, lymphoid and intestinal | |
| H462 | 118 | Enterocolitis | |
| 18685 | B*29 | 39 | Bacterial endocarditis with microabscesses |
| 18894 | 84 | Enteritis, mild SIVE, interstitial nephritis, LD | |
| Env | |||
| H422 | 450+ | Healthy | |
| H424 | 72 | Protozoal enteritis, interstitial pneumonia, SIV | |
| H453 | B*29 | 66 | Pneumocystis pneumonia, LD |
| H456 | B*29 | 450+ | Low CD4 cell count |
| 18679 | 70 | Multicentric lymphoma (liver, kidneys, heart) | |
| 18681 | 149 | Endocarditis, enteritis with intestinal amyloidosis | |
| Gag-Pol-Env | |||
| H425 | B*29 | 73 | Enteritis (Strongyloides), lymphoma |
| H427 | 120 | Enteritis, LD | |
| H448 | 123 | Enteritis | |
| H452b | 225 | Suppurative arthritis, all other tissues WNL | |
| 18661 | B*08 | 75 | Pneumocystis enteritis with amyloid (LP) |
| 18673 | A*01, B*29 | 365 | Cryptosporidial cholecystitis, pancreatitis, intestinal amyloidosis, colitis |
| Control | |||
| H386b | A*01 | 16 | Anesthetic death, not SIV related |
| H387 | 32 | Severe bilateral bacterial pyelonephritis, LD | |
| H426 | 23 | SIVE and SIV pneumonia | |
| H428 | 150 | Cholangiohepatitis and enteritis (Cryptosporidium) | |
| 18654 | B*08 | 58 | Severe enteritis with edema, crypt abscesses |
| 18655 | 16 | SIVE and SIV pneumonia |
a
All animals were genotyped for three of the MHC-I alleles associated with control of viremia and slow disease progression in SIV-infected macaques, Mamu-A*01, -B*08, and -B*29, as described in Materials and Methods.
b
Premature death, not directly related to SIV infection.
c
SIVE, SIV encephalitis; LD, lymphoid depletion; NA, not applicable; WNL, within normal limit; LP, lamina propria.